Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) had its price target lowered by analysts at Mizuho from $28.00 to $26.00.
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- Tavapadon for Parkinson's Disease for 7MM: Market Size, Forecast, and Emerging Insights 2019-2032 - Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan [Yahoo! Finance]Yahoo! Finance
- AbbVie slips after revising guidance to reflect earnings impact [Seeking Alpha]Seeking Alpha
- Global Parkinson Disease Market Projected to Reach $8.8 Billion by 2030, Driven by Advancements and Growing Demand for Effective Treatments [Yahoo! Finance]Yahoo! Finance
- Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? [Yahoo! Finance]Yahoo! Finance
- Director N Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings Inc (CERE) [Yahoo! Finance]Yahoo! Finance
CERE
Earnings
- 11/1/23 - Beat
CERE
Sec Filings
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- 3/4/24 - Form 4
- CERE's page on the SEC website